Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: A new avenue for a disease modifying treatment of Alzheimers?

ACS Chemical Neuroscience

Volumn 3, Issue 11, 2012, Pages 857-872

  Smith, Breland ^a,b   Medda, Federico ^b   Gokhale, Vijay ^b   Dunckley, Travis ^c   Hulme, Christopher ^a,b  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimers disease; Down syndrome; DYRK1A; DYRK1A inhibitors

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2,4 DIAMINOQUINAZOLINE DERIVATIVE; 3 (2 AMINOPYRIMIDIN 4 YL)INDOLE; 3 (6 HYDROXYINDOL 2 YL) 5 (PHENYL) PYRIDINE; 3 (PYRIMIDIN 4 YL) 7 AZAINDOLE; 3,6 DIAMINO 1H PYRAZOLO[3,4 B]PYRIDINE; 4,5,6,7 TETRABROMO 1H BENZIMIDAZOLE; 4,5,6,7 TETRABROMO 1H BENZOTRIAZOLE; 4,5,6,7 TETRABROMO 2 DIMETHYLAMINO 1H BENZIMIDAZOLE; 4,5,6,7 TETRAHALOGENO 1H ISOINDOLE 1,3(2H) DIONE; 9 ETHYLHARMINE; A 443654; ACANILOL A; ACANILOL B; BENZOCOUMARIN; BETA CARBOLINE; CHROMENO[3,4B]INDOLE; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A INHIBITOR; ENZYME INHIBITOR; EPIGALLOCATECHIN GALLATE; ERLOTINIB; HARMINE; HARMOL; PURLAVANOL A; QUINALIZARIN; QUINAZOLINE; REBECCAMYCIN; STAUROSPORINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARIOLIN;

ALZHEIMER DISEASE; ANTIFUNGAL ACTIVITY; CHROMOSOME 21; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DOWN SYNDROME; DRUG STRUCTURE; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A GENE; GENE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ANTHRAQUINONES; BIOMEDICAL RESEARCH; CARBOLINES; CATECHIN; CHROMOSOMES, HUMAN, PAIR 21; COUMARINS; DOWN SYNDROME; DRUG DESIGN; HUMANS; MICE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; TAU PROTEINS;

EID: 84869782889     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn300094k     Document Type: Review

References (124)

1. Becker, W. and Joost, H. G. (1999) Structural and Functional Characteristics of DYRK, a Novel Family of Protein Kinases with Dual Specificity Prog. Nucleic Acid Res. 62, 1-17
2. Becker, W. and Sippl, W. (2011) Activation, Regulation, and Inhibition of DYRK-1A FEBS J. 278, 246-256
3. Aranda, S., Laguna, A., and de la Luna, S. (2011) DYRK Family of Protein Kinases: Evolutionary Relationships, Biochemical Properties, and Functional Roles FASEB J. 25, 449-462
4. Tejedor, F. J. and Hammerle, B. (2010) MNB/DYRK1A as a Multiple Regulator of Neuronal Development FEBS J. 278, 223-235
5. Park, J., Song, W. J., and Chung, K. C. (2009) Function and Regulation of DYRK1A: Towards Understanding Down Syndrome Cell. Mol. Life Sci. 66, 3235-3240
6. Martí, E., Altafaj, X., Dierssen, M., de la Luna, S., Fotaki, V., Alvarez, M., Pérez-Riba, M., Ferrer, I., and Estivill, X. (2003) Dyrk1A Expression Pattern Supports Specific Roles of this Kinase in the Adult Central Nervous System Brain Res. 964, 250-263
7. Fotaki, V., Martínez De Lagrán, M., Estivill, X., Arbonés, M., and Dierssen, M. (2004) Haploinsufficiency of DYRK1A in Mice Leads to Specific Alterations in the Development and Regulation of Motor Activity Behav. Neurosci. 118, 815-821
8. Fotaki, V., Dierssen, M., Alcántara, S., Martínez, S., Martí, E., Casas, C., Visa, J., Soriano, E., Estivill, X., and Arbonés, M. L. (2002) DYRK1A Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice Mol. Cell. Biol. 22, 6636-6647
9. Benavides-Piccione, R., Dierssen, M., Ballesteros-Yáñez, I., Martínez de Lagrán, M., Arbonés, M. L., Fotaki, V., DeFelipe, J., and Elston, G. N. (2005) Alterations in the Phenotype of Neocortical Pyramidal Cells in the DYRK1Aα Mouse Neurobiol. Dis. 20, 115-122
10. Martinez de Lagran, M., Bortolozzi, A., Millan, O., Gispert, J. D., Gonzalez, J. R., Arbones, M. L., Artigas, F., and Dierssen, M. (2007) Dopaminergic Deficiency in Mice with Reduced Levels of the Dual-Specificity Tyrosine-Phosphorylated and Regulated Kinase 1A, DYRK1A(α) Genes Brain Behav. 6, 569-578
11. Arqué, G., Fotaki, V., Fernández, D., Martínez de Lagrán, M., Arbonés, M. L., and Dierssen, M. (2008) Impaired Spatial Learning Strategies and Novel Object Recognition in Mice Haploinsufficient for the Dual Specificity Tyrosine-Regulated Kinase-1A (DYRK1A) PLoS One 3, e2575
12. Hardy, J. A. and Higgins, G. A. (1992) Alzheimers Disease: The Amyloid Cascade Hypothesis Science 256, 184-185
13. Selkoe, D. (2001) Presenilins, β-Amyloid Precursor Protein and the Molecular Basis of Alzheimers Disease Clin. Neurosci. Res. 1, 91-103
14. Hardy, J. (2001) Genetic Dissection of Neurodegenerative Disease Clin. Neurosci. Res. 1, 134-141
15. Tirabhschi, P., Hansen, L. A., Thai, L. J., and Corey-Bloom, J. (2004) The Importance of Neuritic Plaques and Tangles to the Development and Evolution of AD Neurology 62, 1984-1989
16. Johnson, G. V. and Hartigan, J. A. (1999) Tau Protein in Normal and Alzheimers Disease Brain: An Update J. Alzheimer's Dis. 1, 329-351
17. Neugroschl, J. and Sano, M. (2010) Current Treatment and Recent Clinical Research in Alzheimers Disease Mt. Sinai J. Med. 77, 3-16
18. De Strooper, B., Vassar, R., and Golde, T. (2010) The Secretases: Enzymes with Therapeutic Potential in Alzhiemer Disease Nat. Rev. Neurol. 6, 99-107
19. Song, W. J., Sternberg, L. R., Kasten-Sportés, C., Van Keuren, M. L., Chung, S. H., Slack, A. C., Miller, D. E., Glover, T. W., Chiang, P. W., Lou, L., and Kurnit, D. M. (1996) Isolation of Human and Murine Homologues of the Drosphila Minibrain Gene: Human Homologue Maps to 21q22.2 in the Down Syndrome "Critical Region Genomics 38, 331-339
20. Wegiel, J., Gong, C. X., and Hwang, Y. W. (2011) The Role of DYRK1A in Neurodegenerative Diseases FEBS J. 278, 236-245
21. Dierssen, M. and Martínez de Lagrán, M. (2006) DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and Neurogenesis TheScientificWorldJournal 6, 1911-1922
22. Trinczek, B., Biernat, J., Baumann, K., Mandelkow, E. M., and Mandelkow, E. (1995) Domains of Tau Protein, Differential Phosphorylation and Dynamic Instability of Microtubules Mol. Biol. Cell 6, 1887-1902
23. Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., and Hyman, B. T. (1992) Neurofibrillary Tangles but not Senile Plaques Parallel Duration and Severity of Alzheimers Disease Neurology 42, 631-639
24. Hitchcock, S. A. and Pennington, L. D. (2006) Structure-Brain Exposure Relationships J. Med. Chem. 49, 7559-7583
25. Traxler, P. and Furet, P. (1999) Strategies Toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors Pharmacol. Ther. 82, 195-206
26. Liu, Y. and Gray, N. S. (2006) Rational Design of Inhibitors that Bind to Inactive Kinase Conformations Nat. Chem. Biol. Perspect. 2, 358-364
27. Ferrer, I., Barrachina, M., Puig, B., Martinez de Lagran, M., Marti, E., Avila, J., and Dierssen, M. (2005) Constitutive DYRK1A is Abnormally Expressed in Alzheimer Disease, Down Syndrome, Pick Disease, and Related Trangenic Models Neurobiol. Dis. 20, 392-400
28. Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., and Davisson, M. T. (1995) A Mouse Model for Down Syndrome Exhibits Learning and Behaviour Deficits Nat. Genet. 11, 177-184
29. Sago, H., Carlson, E. J., Smith, D. J., Kilbridge, J., Rubin, E. M., Mobley, W. C., Epstein, C. J., and Huang, T. T. (1998) Ts1Cje, a Partial Trisomy 16 Mouse Model for Down Syndrome, Exhibits Learning and Behavioral Abnormalities Proc. Natl. Acad. Sci. U.S.A. 95, 6256-6261
30. Belichenko, N. P., Belichenko, P. V., Kleschevnikov, A. M., Salehi, A., Reeves, R. H., and Mobley, W. C. (2009) The "Down Syndrome Critical Region" is Sufficient in the Mouse Model to Confer Behavioral, Neurophysiological, and Synaptic Phenotypes Characteristic of Down Syndrome J. Neurosci. 29, 5938-5948
31. Belichenko, P. V., Masliah, E., Kleschevnikov, A. M., Villar, A. J., Epstein, C. J., Salehi, A., and Mobley, W. C. (2004) Synaptic Structural Abnormalities in the Ts65Dn Mouse Model of Down Syndrome J. Comp. Neurol. 480, 281-298
32. Belchenko, P. V., Kleschevnikov, A. M., Salehi, A., Epstein, C. J., and Mobley, W. C. (2007) Synaptic and Cognitive Abnormalities in Mouse Models of Down Syndrome: Exploring Genotype, Phenotype Relationships J. Comp. Neurol. 504, 329-345
33. Siarey, R. J., Stoll, J., Rapoport, S. I., and Galdzicki, Z. (1997) Altered Long Term Potentiation in the Young and Old Ts65Dn Mouse, a Model for Down Syndrome Neuropharmacology 36, 1549-1554
34. Siarey, R. J., Villar, A. J., Epstein, C. J., and Galdzicki, Z. (2005) Abnormal Synaptic Plasticity in the Ts1Cje Segmental Trisomy 16 Mouse Model of Down Syndrome Neuropharmacology 49, 122-128
35. Smith, D. J., Stevens, M. E., Sudanagunta, S. P., Bronson, R. T., Makhinson, M., Watabe, A. M., ODell, T. J., Fung, J., Weier, H. U., Cheng, J. F., and Rubin, E. M. (1997) Functional Screening of 2 Mb of Human Chromosome 21q22.2 in Transgenic Mice Implicates Minibrain in Learning Deficits Associated with Down Syndrome Nat. Genet. 16, 28-36
36. Branchi, I., Bichler, Z., Minghetti, L., Delabar, J. M., Malchoidi-Abedi, F., Gonzalez, M. C., Chettouh, C., Niccolini, A., Chabert, C., Smith, D. J., Rubin, E. M., Migliore-Samour, D., and Alleva, E. (2004) Transgenic Mice in vivo Library of Human Down Syndrome Critical Region 1: Association Between DYRK1A Overexpression, Brain Development Abnormalities, and Cell Cycle Protein Alteration J. Neuropathol. Exp. Neurol. 63, 429-440
37. Chabert, C., Jamon, M., Cherfouh, A., Duquenne, V., Smith, D. J., Rubin, E., and Roubertoux, P. L. (2004) Functional Analysis of Genes Implicated in Down Syndrome: I. Cognitive Abilities in Mice Transpolygenic for Down Syndrome Chromosomal Region 1 (DSR-1) Behav. Genet. 34, 559-569
38. Ahn, K. J., Jeong, H. K., Choi, H. S., Ryoo, S. R., Kim, Y. J., Goo, J. S., Choi, S. Y., Han, J. S., Ha, I., and Song, W. J. (2006) DYRK1A BAC Transgenic Mice Show Altered Synaptic Plasticity with Learning and Memory Defects Neurobiol. Dis. 22, 463-472
39. Altafaj, X., Dierssen, M., Baamonde, C., Marti, E., Visa, J., Guimera, J., Oset, M., Gonzalez, J. R., Florez, J., Fillat, C., and Estevill, X. (2001) Neuronal Developmental Delay, Motor Abnormalities, and Cognitive Deficits in Transgenic Mice Overexpressing DYRK1A (minibrain), a Murine Model of Down Syndrome Hum. Mol. Genet. 10, 1915-1923
40. Wegiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, A., Wang, K. C., Wegiel, J., Yang, S. M., Frackowiak, J., Mazur-Kolecka, B., Silverman, W. P., Reisberg, B., Monteiro, I., de Leon, M., Wisniewski, T., Dalton, A., Lai, F., Hwang, Y. W., Adayev, T., Liu, F., Iqbal, K., Iqbal, I. G., and Gong, C. X. (2011) Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration with 3-Repeat Tau Protein in Down Syndrome J. Neuropathol. Exp. Neurol. 70, 36-50
41. Wegiel, J., Dowiat, K., Kaczmarski, W., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur-Kolecka, B., Wegiel, J., Silverman, W. P., Reisberg, B., Deleon, M., Wisniewski, T., Gong, C. X., Liu, F., Adayev, T., Chen-Hwang, M. C., and Hwang, Y. W. (2008) The Role of Overexpressed DYRK1A Protein in the Early Onset of Neurofibrillary Degeneration in Down Syndrome Acta Neuropathol. 116, 391-407
42. Woods, Y. L., Cohen, P., Becker, W., Jakes, R., Goedert, M., Wang, X., and Proud, C. G. (2001) The Kinase DYRK Phosphorylates Protein-Synthesis Initiation Factor elF2B at Ser539 and the Microtubule-Associated Protein Tau at Thr212: Potential Role for DYRK as a Glycogen Synthase Kinase 3-Priming Kinase Biochem. J. 355, 609-615
43. Liu, F., Liang, Z., Wegiel, J., Hwang, Y. W., Iqbal, K., Grundke-Iqbal, I., Ramakrishna, N., and Gong, C. X. (2008) Overexpression of Dyrk1A Contributes to Neurofibrillary Degeneration in Down Syndrome FASEB J. 22, 3224-3233
44. Azorsa, D. O., Robeson, R. H., Frost, D., Meechoovet, B., Brautigam, G. R., Dickey, C., Beaudry, C., Basu, G. D., Holz, D. R., Hernandez, J. A., Bisanz, K. M., Gwinn, L., Grover, A., Rogers, J., Reiman, E. M., Hutton, M., Stephan, D. A., Mousses, D., and Dunckley, T. (2010) High-Content siRNA Screening of the Kinome Identifies Kinases Involved in Alzheimers Disease-Related Tau Hyperphosphorylation BMC Genomics 11, 25
45. Frost, D., Meechoovet, B., Wang, T., Gately, S., Giorgetti, M., Shcherbakova, I., and Dunckley, T. (2011) β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimers Disease-Related Sites PLoS One 6, e19264
46. Shi, J., Zhang, T., Zhou, C., Chohan, M. O., Gu, X., Wegiel, J., Zhou, J., Hwang, Y. W., Iqbal, K., Grundke-Iqbal, I., Gong, C. X., and Liu, F. (2008) Increased Dosage of DYRK1A Alters Alternative Splicing Factor (ASF)-Regulated Alternative Splicing of Tau in Down Syndrome J. Biol. Chem. 283, 28660-28669
47. Goedert, M. and Jakes, R. (2005) Mutations Causing Neurodegenerative Tauopathies Biochem. Biophys. Acta 1739, 240-250
48. Jung, M. S., Park, J. H., Ryu, Y. S., Choi, S. H., Yoon, S. H., Kwen, M. Y., Oh, J. Y., Song, W. J., and Chung, S. H. (2011) Regulation of RCAN-1 Protein Activity by DYRK1A Protein-Mediated Phosphorylation J. Biol. Chem. 286, 40401-40412
49. Park, J., Oh, Y., and Chung, K. C. (2009) Two Key Genes Closely Implicated with the Neuropathological Characteristics in Down Syndrome: DYRK1A and RCAN1 BMB Rep. 42, 6-15
50. Ryoo, S. R., Cho, H. J., Lee, H. W., Jeong, H. K., Radnaabazar, C., Kim, Y. S., Kim, M. J., Son, M. J., Seo, H., Chung, S. H., and Song, W. J. (2008) DYRK1A-Mediated Phosphorylation of Amyloid Precursor Protein: Evidence for a Functional Link Between Down Syndrome and Alzheimers Disease J. Neurochem. 104, 1333-1344
51. Ryoo, S. R., Jeong, H. K., Radnaabazar, C., Yoo, J. J., Cho, H. J., Lee, H. W., Kim, I. S., Cheon, Y. H., Ahn, Y. S., Chung, S. H., and Song, W. J. (2007) DYRK1A-Mediated Hyperphosphorylation of Tau: A Functional Link Between Down Syndrome and Alzheimer Disease J. Biol. Chem. 282, 34850-34857
52. Ryu, Y. S., Park, S. Y., Jung, M. S., Yoon, S. H., Kwen, M. Y., Lee, S. Y., Choi, S. H., Radnabaazar, C., Kim, M. K., Kim, H., Kim, K., Song, W. J., and Chung, S. H. (2010) DYRK1A Mediated Phosphorylation of Presnilin-1: A Functional Link Between Down Syndrome and Alzhemers Disease J. Neurochem. 115, 574-584
53. Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., Tabara, Y., Miki, T., Akatsu, H., Kosaka, K., Funakoshi, E., Nishitomi, K., Sakaguchi, G., Kato, A., Hattori, H., Uema, T., and Takeda, M. (2007) The DYRK1A Gene, Encoded in Chromosome 21 Down Syndrome Critical Region, Bridges Between β-Amyloid Production and Tau Phosphorylating in Alzheimers Disease Hum. Mol. Genet. 16, 15-23
54. Guedi, F., Pereira, P. L., Najas, S., Barallobre, M. J., Chabert, C., Souchet, B., Sebrie, C., Verney, C., Herault, Y., Arbones, M., and Delabar, J. M. (2012) DYRK1A: A Master Regulatory Protein Controlling Brain Growth Neurobiol. Dis. 46, 190-203
55. Choi, H. K. and Chung, K. C. (2011) DYRK1A Positively Stimulates ASK1-JNK Signaling Pathway during Apoptotic Cell Death Exp. Neurobiol. 20, 35-44
56. Park, J., Oh, Y., Yoo, L., Jung, M. S., Song, W. J., Lee, S. H., Seo, H., and Chung, K. C. (2010) DYRK1A Phosphorylates p53 and Inhibits Proliferation of Embryonic Neuronal Cells J. Biol. Chem. 285, 31895-31906
57. Murakama, N., Xie, W., Lu, R. C., Chen-Hwang, M. C., Wieraszko, A., and Hwang, Y. U. (2006) Phosphorylation of Amphiphysin I by Minibrain Kinase/Dual-Specificity Tyrosine Phosphorylation Regulated Kinase, a Kinase Implicated in Down Syndrome J. Biol. Chem. 281, 23712-23724
58. Kim, E. J., Sung, J. Y., Lee, H. J., Rhim, H., Hasegawa, M., Iwatsubo, T., Min, D. S., Kim, J., Paik, S. R., and Chung, K. C. (2006) DYRK1A Phosphorylates α-Synuclein and Enhances Intracellular Inclusion Formation J. Biol. Chem. 281, 33250-33257
59. Kang, J. E., Choi, S. A., Park, J. B., and Chung, K. C. (2005) Regulation of the Proapoptotic Activity of Huntingtin Interacting Protein 1 by DYRK1A and Caspase-3 in Hippocampal Neuroprogenitor Cells J. Neurosci. Res. 81, 62-72
60. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, J., McLauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., and Cohen, P. (2007) The Selectivity of Protein Kinase Inhibitors: A Further Update Biochem. J. 408, 297-315
61. Gockler, N., Guillermo, J., Papadopoulos, C., Soppa, U., Tejador, F. J., and Becker, W. (2009) Harmine Specifically Inhibits Protein Kinase DYRK1A and Interferes with Neurite Formation FEBS J. 276, 6324-6337
62. Callaway, J. C., McKenna, D. J., Grob, C. S., Brito, G. S., Raymon, L. P., Poland, R. E., Andrade, E. N., Andrade, E. O., and Mash, D. C. (1999) Pharmacokinetics of Hoasca Alkaloids in Healthy Humans J. Ethnopharmacol. 65, 243-256
63. Gambelunghe, C., Aroni, K., Rossi, R., Moretti, L., and Bacci, M. (2008) Identification of N,N -Dimethyltryptamine and β-Carbolines in Psychotropic Ayahuasca Beverage Biomed. Chromatogr. 22, 1056-1059
64. Airaksinen, M. M., Lecklin, A., Saano, V., Tuomisto, L., and Gynther, J. (1987) Tremorigenic Effect and Inhibition of Tryptamine and Serotonin Receptor Binding by β-Carbolines Pharmacol. Toxicol. 60, 5-8
65. Fuentes, J. A. and Longo, V. G. (1971) An Investigation of the Central Effects of Harmine, Harmaline, and Related β-Carbolines Neuropharmacology 10, 15-23
66. Kawanishi, K., Eguchi, N., Hayashi, T., and Hashimoto, Y. (1994) Relationship Between Occurrence of Tremor/Convulsion and Level of β-Carbolines Into Mice Pharmacol., Biochem. Behav. 47, 689-699
67. Albores, R., Neafsey, E. J., Drucker, G., Fields, J. Z., and Collins, M. A. (1990) Mitochondrial Respiratory Inhibition by N-Methylated Beta-Carboline Derivatives Structurally Resembling N-Methyl-4-Phenylpyridine Proc. Natl. Acad. Sci. U.S.A. 87, 9368-9372
68. Kim, H., Sablin, S. O., and Ramsay, R. R. (1997) Inhibition of Monoamine Oxidase A by β-Carboline Derivatives Arch. Biochem. Biophys. 337, 137-142
69. Samoylenko, V., Rahman, M., Tekwani, B. L., Tripathi, L. M., Wang, Y.-H., Khan, S. I., Khan, I. A., Miller, L. S., Joshi, V. C., and Muhammad, I. (2010) Banisteriopsis caapi, a Unique Combination of MAO Inhibitory and Antioxidative Constituents for the Activities Relevant to Neurodegenerative Disorders and Parkinsons Disease J. Ethnopharmacol. 127, 357-367
70. Reniers, J., Robert, S., Frederick, R., Masereel, B., Vincent, S., and Wouters, J. (2011) Synthesis and Evaluation of β-Carboline Derivatives as Potential Monoamine Oxidase Inhibitors Bioorg. Med. Chem. Lett. 19, 134-144
71. Bain, J., McLauchlan, H., Elliott, M., and Cohen, P. (2003) The Specificities of Protein Kinase Inhibitors: An Update Biochem. J. 371, 199-204
72. Adayev, T., Chen-Hwang, M. C., Murakami, N., Wegiel, J., and Hwang, Y.-W. (2006) Kinetic Properties of a MNB/DYRK1A Mutant Suitable for the Elucidation of Biochemical Pathways Biochemistry 45, 12011-12019
73. Guedj, F., Sébrié, C., Rivals, I., Ledru, A., Paly, E., Bizot, J. C., Smith, D., Rubin, E., Gillet, B., Arbones, M., and Delabar, J. M. (2009) Green Tea Polyphenols Rescue of Brain Deficits Induced by Overexpression of DYRK1A PLoS One 4 (1-8) e4606
74. Hamilton-Miller, J. M. (1995) Antimicrobial Properties of Tea (Camellia sinesis L.) Antimicrob. Agents Chemother. 39, 2375-2377
75. Yam, T. S., Shah, S., and Hamilton-Miller, J. M. (1997) Microbiological Activity of Whole and Fractionated Crude Extracts of Tea (Camella Sinesis), and of Tea Components FEMS Microbiol. Lett. 152, 169-174
76. Toda, M., Okubo, S., Hiyoshi, R., and Shimamura, T. (1989) The Bacteriocidal Activity of Tea and Coffee Lett. Appl. Microbiol. 8, 123-125
77. Toda, M., Okubo, S., Hara, Y., and Shimamura, T. (1991) Antibacterial and Bacterial Activities of Tea Extracts and Catechins Against Methicillin Resistant Staphylococcus Aureus Nihon Saikingaku, Zasshi 46, 839-845
78. Toda, M., Okubo, S., Ikigai, H., Suzuki, Y., Hara, Y., and Shimamura, T. (1992) The Protective Activity of Tea Catechins Against Experimental Infection by Vibrio cholerae O1 Microbiol. Immunol. 36, 999-1001
79. Chosa, H., Toda, M., Okubo, S., Hara, Y., and Shimamura, T. (1992) Antimicrobial and Microbicidal Activities of Tea and Catechin Against Micoplasma Kansenshogaku Zasshi 66, 606-611
80. Horiuchi, Y., Toda, M., Okubo, S., Hara, Y., and Shimamura, T. (1992) Protective Activity of Tea and Catechin Against Bordetella Pertussis Kansenshogaku Zasshi 66, 599-605
81. Okubo, S., Sakaki, T., Hara, Y., Mori, F., and Shimamura, T. (1998) Bacteridal and Anti-Toxin Activities of Catechin on Enterohemorrhagic Escherichia coli Kansenshogaku Zasshi 72, 211-217
82. John, T. J. and Mukundan, P. (1979) Virus Inhibition by Tea, Caffeine, and Tannic Acid Indian J. Med. Res. 68, 542-545
83. Mukoyama, A., Ushijima, H., Nishimura, S., Koike, H., Toda, M., Hara, Y., and Shimamura, T. (1991) Inhibition of Rotavirus and Enterovirus Infections by Tea Extracts Jpn. J. Med. Sci. Biol. 44, 181-186
84. Nakayama, M., Suzuki, K., Toda, M., Okubo, S., Hara, Y., and Shimamura, T. (1993) Inhibition of the Infectivity of Influenza Virus by Tea Polyphenols Antiviral Res. 21, 289-299
85. Yamaguchi, K., Honda, M., Ikigai, H., Hara, Y., and Shimamura, T. (2002) Inhibitory Effects of (-)-Epigallocatechin gallate on the Life Cycle of Human Immunodeficiency Virus Type 1 (HIV-1) Antiviral Res. 53, 19-34
86. Williamson, M. P., McCormick, T. G., Nance, C. L., and Shearer, W. T. (2006) Epigallocatechin gallate, the Main Polyphenol in Green Tea, Binds to the T-Cell Receptor, CD4: Potential for HIV-1 Therapy J. Allergy Clin. Immunol. 118, 1369-1374
87. Hamza, A. and Zhan, C. G. (2006) How Can (-)-Epigallocatechin gallate from Green Tea Prevent HIV-1 Infection? Mechanistic Insights from Computational Modeling and the Implication for Rational Design of Anti-HIV-1 Entry Inhibitors J. Phys. Chem. B 110, 2910-2917
88. Okubo, S., Toda, M., Hara, Y., and Shimamura, T. (1991) Antifungal and Fungicidal Activities of Tea Extract and Catechin Against Trichophyton Nihon Saikingaku Zassi 46, 509-514
89. Okubo, S., Ikigai, H., Toda, M., and Shimimura, T. (1989) The Anti-Hemolysin Activity of Tea and Coffee Lett. Appl. Microbiol. 9, 65-66
90. Ikigai, H., Toda, M., Okubo, S., Hara, Y., and Shimiura, T. (1990) Relationship Between the Anti-Hemolysin Activity and the Structure of Catechins and Theaflavins Nihon Saikingaku Zassi 45, 913-919
91. Toda, M., Okubo, S., Ikigai, H., and Shimamura, T. (1990) Antibacterial and Anti-Hemolysin Activities of Tea Catechins and their Structural Relatives Nihon Saikingaku Zassi 45, 561-566
92. Bandele, O. J. and Osheroff, N. (2008) (-)-Epigallocatechin gallate, a Major Constituent of Green Tea, Poisons Human Type II Topoisomerases Chem. Res. Toxicol. 21, 936-943
93. Chen, L. and Zhang, H. Y. (2007) Cancer Preventive Mechanisms of the Green Tea Polyphenol (-)-Epigaollcatechin-3-gallate Molecules 12, 946-957
94. Leone, M., Zhai, D., Sareth, S., Kitada, S., Reed, J. C., and Pellecchia, M. (2003) Cancer Prevention by Tea Polyphenols is Linked to Their Direct Inhibition of Antiapoptotic Bcl-2-Family Proteins Cancer Res. 63, 8118-8121
95. Jankun, T. J., Selma, S. H., Swjercz, R., and Skrzypczak-Jankun, E. (1997) Why Drinking Green Tea Could Prevent Cancer Nature 387, 561
96. Lin, Y. L. and Lin, J. K. (1997) (-)-Epigallocatechin-3-gallate Blocks the Induction of Nitric Oxide Synthase by Down-Regulating Lipopolysaccharide Induced Activity of Transcription Factor Nuclear Factor-κB Mol. Pharmacol. 52, 465-472
97. Cozza, G., Mazzorana, M., Papinutto, E., Bain, J., Elliott, M., di Maira, G., Gianoncelli, A., Pagano, M. A., Sarno, S., Ruzenne, M., Battistutta, R., Meggio, F., Moro, S., and Zagotto, G. (2009) Quinalizarin as a Potent, Selective, and Cell Permeable Inhibitor of Protein Kinase CK2 Biochem. J. 421, 387-395
98. Ahmadu, A., Abdulkarim, A., Grougnet, R., Myrianthopoulos, V., Tillequin, F., Magiatis, P., and Skaltsounis, A.-L. (2010) Two New Peltogynoids from Acacia nilotica with Kinase Inhibitor Activity Planta Med. 76, 458-460
99. Sarno, S., Mazzorana, M., Traynor, R., Ruzzene, M., Cozza, G., Pagano, M. A., Meggio, F., Zagotto, G., Battistutta, R., and Pinna, L. A. (2012) Structural Features Underlying the Selectivity of the Kinase Inhibitors NBC and dNBC: Role of a Nitro Group that Discriminates Between CK2 and DYRK1A Cell. Mol. Life Sci. 69, 449-60
100. Sánchez, C., Salas, A. P., Braña, A. F., Palomino, M., Pineda-Lucena, A., Carbajo, R. J., Méndez, C., Moris, F., and Sala, J. A. (2009) Generation of Potent and Selective Kinase Inhibitors by Combinatorial Biosynthesis of Glycosylated Indolocarbazoles Chem. Commun. 27, 4118-4120
101. Kim, N. D., Yoon, J., Kim, J. H., Lee, J. T., Chon, Y. S., Hwang, M.-K., Ha, I., and Song, W.-J. (2006) Putative Therapeutic Agents for the Learning and Memory Deficits of People with Down Syndrome Bioorg. Med. Chem. Lett. 16, 3772-3776
102. Kyng, A. K., Kim, N. D., Chon, Y. S., Jung, M.-S., Lee, B.-J., Kim, J. H., and Song, W.-J. (2009) QSAR Analysis of Pyrazolidine-3,5-Diones Derivatives as Dyrk1A Inhibitors Bioorg. Med. Chem. Lett. 19, 2324-2328
103. Mott, B. T., Tanega, C., Shen, M., Maloney, D. J., Shinn, P., Leister, W., Marugan, J. J., Inglese, J., Austin, C. P., Misteli, T., Auld, D. S., and Thomas, C. T. (2009) Evaluation of Substituted 6-ArylQuinazoline-4-Amines as Potent and Selective Inhibitors of Cdc2-Like Kinases (Clk) Bioorg. Med. Chem. 19, 6700-6705
104. Rosenthal, A. S., Tanega, C., Shen, M., Mott, B. T., Bougie, J. M., Nguyen, D.-T., Misteli, T., Auld, D. S., Maloney, D. J., and Thomas, C. J. (2011) Potent and Selective Small Molecule Inhibitors of Specific Isoforms of Cdc2-Like Kinases (Clk) and Dual Specificity Tyrosine-Phosphorylation Regulated Kinases (Dyrk) Bioorg. Med. Chem. Lett. 21, 3152-3158
105. Ogawa, Y., Nonaka, Y., Goto, T., Ohnishi, E., Hiramatsu, T., Kii, I., Yoshida, M., Ikura, T., Onogi, H., Shibuya, H., Hosoya, T., Ito, N., and Hagiwara, M. (2010) Development of a Novel Selective Inhibitor of the Down Syndrome-Related Kinase DYRK1A Nat. Commun. 86, 1-9
106. Arron, J. R., Winslow, M. M., Polleri, A., Chang, C. P., Wu, H., Gao, X., Neilson, J. R., Chen, L., Heit, J. J., Kim, S. K., Yamasaki, N., Mikawa, T., Francke, U., Graef, I. A., and Crabtree, G. R. (2006) NFAT Dysregulation by Increased Dosage of DSCR1 and DYRK1A on Chromosome 21 Nature 441, 595-600
107. Echalier, A., Bettayeb, K., Ferandin, Y., Lozach, O., Clément, M., Valette, A., Liger, F., Marquet, B., Morris, J. C., Endicott, J. A., Joseph, B., and Meijer, L. (2008) Meriolins (3-Pyrimidin-4-yl-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of CDK2/Cyclin A/Meriolin Complex J. Med. Chem. 51, 737-7541
108. Akue-Gedu, R., Debiton, E., Ferandin, Y., Meijer, L., Prudhomme, M., and Anizon, F. (2009) Synthesis and Biological Activities of Aminopyrimidyl-Indoles Structurally Related to Meridianins Bioorg. Med. Chem. Lett. 17, 4420-4424
109. Giraud, F., Alves, G., Debiton, E., Nauton, L., Théry, V., Durieu, E., Ferandin, Y., Lozach, O., Meijer, L., Anizon, F., Pereira, E., and Moreau, P. (2011) Synthesis, Protein Kinase Inhibitory Potencies, and in vitro Antiproliferative Activities of Meridianin Derivatives J. Med. Chem. 54, 4474-4489
110. Kassis, P., Brzeszcz, J., Bénéteau, V., Lozach, O., Meijer, L., Guével, R. L., Guillouzo, C., Lewiński, K., Bourg, S., Colliandre, L., Routier, S., and Mérour, J.-Y. (2011) Synthesis and Biological Evaluation of New 3-(6-hydroxyindol-2-yl)-5-(Phenyl) Pyridine or Pyrazine V-Shaped Molecules as Kinase Inhibitors and Cytotoxic Agents Eur. J. Med. Chem. 46, 5416-5434
111. Neagoi, C., Vedrenne, E., Buron, F., Mérour, J.-Y., Rosca, S., Bourg, S., Lozach, O., Meijer, L., Baldeyrou, B., Lansiaux, A., and Routier, S. (2012) Synthesis of Chromeno[3,4b]Indoles as Lamellarin D Analogues: A Novel DYRK1A Inhibitor Class Eur. J. Med. Chem. 49, 379-396
112. Wang, D., Wang, F., Tan, Y., Dong, L., Chen, L., Zhu, W., and Wang, H. (2012) Discovery of Potent Small Molecule Inhibitors of DYRK1A by Structure Based Virtual Screening and Bioassay Bioorg. Med. Chem. Lett. 22, 168-171
113. Knockaert, M., Greengard, P., and Meijer, L. (2002) Pharmacological Inhibitors of Cyclin-Dependent Kinases Trends Pharmacol. Sci. 23, 417-425
114. Meijer, L., Flajolet, M., and Greengard, P. (2004) Pharmacological Inhibitors of Glycogen Synthase Kinase 3 Trends Pharmacol. Sci. 25, 471-480
115. Schwab, C., DeMaggio, A. J., Ghoshal, N., Binder, L. I., Kuret, J., and McGeer, P. L. (2000) Casein Kinase 1 Delta is Associated with Pathological Accumulation of Tau in Several Neurodegenerative Diseases Neuobiol. Aging 21, 503-510
116. Knippschild, U., Gocht, A., Wolff, S., Huber, N., Lohler, J., and Stoler, M. (2005) The Casein Kinase 1 Family: Participation in Multiple Cellular Processes in Eukaryotes Cell. Signalling 17, 675-689
117. Beauchard, A., Laborie, H., Rouillard, H., Lozach, O., Ferandin, Y., Guével, R. L., Gugen-Guillouzo, C., Meijer, L., Besson, T., and Thiéry, V. (2009) Synthesis and Kinase Inhibitory Activity of Novel Substituted Indigoids Bioorg. Med. Chem. 17, 6257-6263
118. Chioua, M., Samadi, A., Soriano, E., Lozach, O., Meijer, L., and Marco-Contelles, J. (2009) Synthesis and Biological Evaluation of 3,6-Diamino-1H-Pyrazolo-3,4[b]Pyridine Derivatives as Protein Kinase Inhibitors Bioorg. Med. Chem. Lett. 19, 4566-4569
119. Pagano, M. A., Bain, J., Kazimierczuk, Z., Sarno, S., Ruzzene, M., Di Maira, G., Elliott, M., Orzeszko, A., Cozza, G., Meggio, F., and Pinna, L. A. (2008) The Selectivity of Inhibitors of Protein Kinase CK2: An Update Biochem. J. 415, 353-365
120. Golub, A. G., Yakovenko, O. Y., Prykhodko, A. O., Lukashov, S. S., Bdzhola, V. G., and Yarmoluk, S. M. (2008) Evaluation of 4,5,6,7-tetrahalogeno- 1H-isoindole-1,3(2H)-Diones as Inhibitors of Human Protein Kinase CK2 Biochim. Biophys. Acta 1784, 143-149
121. Extance, A. (2010) Alzheimers Failure Raises Questions About Disease-Modifying Strategies Nat. Rev. Drug Discovery 9, 749-751
122. Green, R. C., Schneider, L. S., Amato, D. A., Beelen, A. P., Wilcock, G., Swabb, E. A., and Zavitz, K. H. (2009) Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients with Mild Alzheimer Disease: A Randomized Controlled Trial JAMA, J. Am. Med. Assoc. 302, 2557-2564
123. Osborne, R. (2008) Myriad Stumbles, Wyeth Closes on Alzheimers Nat. Biotechnol. 26, 841-843
124. Haas, C. (2012) Strategies, Development, and Pitfalls of Therepeutic Options for Alzheimers Disease J. Alzheimer's Dis. 28, 241-281